ArticleFrontiers in medicine2025
Case Report: Progressive interstitial lung disease secondary to Sjögren's disease in a patient with inclusion body myositis complicated by dysphagia-a multidisciplinary approach and therapeutic challenges.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a 78-year-old man with a complex overlap of inclusion body myositis (IBM) and Sjögren's disease (SjD), complicated by interstitial lung disease (ILD) and esophageal dysfunction. The patient's neuromuscular decline was managed with periodic intravenous immunoglobulins (IVIG), while his progressive ILD required a combined immunosuppressive and antifibrotic regimen, including prednisone. This case underscores the diagnostic and therapeutic challenges in managing autoimmune overlap syndromes, particularly the rare coexistence of IBM and SjD-related ILD. We highlight the rationale behind the treatment strategy and the importance of a tailored, multidisciplinary approach in addressing both muscular and pulmonary manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.